TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00346970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT03480243
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use
Study: NCT05429749
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 250ml is administered between the admission day and the surgery day.
Study: NCT04522284
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum total cumulative dose per cycle of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. , 1250mg/m2 twice daily for single agent capecitabine regimen). Minimum total cumulative dose per cycle of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 625mg/m2 twice daily for single agent capecitabine). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
Study: NCT04522284
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum dose of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. 1000 mg/m2 twice daily for XELOX regimen). Minimum dose of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 500 mg/m2 twice daily for XELOX regimen). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range. The doses of other drug in the XELOX regimen (oxaliplatin) will be held constant or adjusted at the clinical investigator's discretion, as per standard of care.
Study: NCT04522284
Drug: XELIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum dose of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. 1000 mg/m2 twice daily for XELIRI regimen). Minimum dose of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 500 mg/m2 twice daily for XELIRI regimen). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.~The doses of other drug in the XELIRI regimen (irinotecan) will be held constant or adjusted at the clinical investigator's discretion, as per standard of care.
Study: NCT01195831
Drug: Xamiol® gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application
Study: NCT00486291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT01209702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to tocilizumab administered intravenously every 4 weeks
Study: NCT00973713
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/d
Study: NCT03934099
Drug: LC350189 formulated capsule
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthine Oxidase Inhibitor
Study: NCT03934099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04088058
Drug: GXHPC1
Approvals — FDA: no, EMA: no, PMDA: no
Description: autologous ADSCs
Study: NCT04074161
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once weekly for 68 weeks
Study: NCT00950820
Drug: Oxaliplatin, Capecitabine, Panitumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
Study: NCT00950820
Drug: Oxaliplatin, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
Study: NCT00160901
Drug: two complex naturopathic add-on therapies, leaflet 5-a-day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02390505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00518089
Drug: placebo eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Study: NCT05517746
Drug: BAY2395840 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, oral administration
Study: NCT05517746
Drug: BAY2395840 oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution, oral administration
Study: NCT05517746
Drug: Placebo oral solution
Normalized name: Placebo Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BAY2395840, oral administration
Study: NCT05517746
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BAY2395840, oral administration
Study: NCT03112577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02177071
Drug: AZATHIOPRINE
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02177071
Drug: MERCAPTOPURINE
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02177071
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01187511
Drug: GSK561679
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verucerfont is a corticotropin releasing hormone receptor 1 (CRF1) antagonist.
Study: NCT01187511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is an inactive tablet design to look exactly like GSK561679
Study: NCT01048034
Drug: Erythropoetin
Normalized name: Erythropoetin zeta
Approvals — FDA: no, EMA: no, PMDA: no
Description: For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
Study: NCT01733680
Drug: amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
Study: NCT02255045
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 Meloxicam Vaginal Ring (MVR) for 4-6 days
Study: NCT02255045
Drug: Diclofenac Potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet 50 mg diclofenac every 12 hours for 4-6 days
Study: NCT02255045
Drug: Placebo Oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo tablet every 12 hours for 4-6 days
Study: NCT02255045
Drug: Placebo Vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo vaginal ring for 4-6 days
Study: NCT03502356
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
Study: NCT02424578
Drug: Diclofenac Capsules low dose
Normalized name: diclofenac Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02424578
Drug: Diclofenac Capsules high dose
Normalized name: diclofenac Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03899467
Drug: GT0918
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-tumor activity
Study: NCT01857934
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV)
Study: NCT00005607
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005607
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005607
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00674440
Drug: F-DOPA
Normalized name: dopa, DL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08-0.16 mCi/kg once
Study: NCT03063931
Drug: Placebo: Lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
Study: NCT00005658
Drug: Glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01247272
Drug: Fluoxetine Hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg Capsules
Study: NCT01247272
Drug: PROZAC WEEKLY®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg Capsules
Study: NCT01436929
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 140mg 1tab bid for 8 weeks
Study: NCT01436929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1tab bid
Study: NCT02213861
Drug: SHAPE
Normalized name: Panshape M
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gel
Study: NCT01163227
Drug: Placebo (single and multiple doses)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01163227
Drug: AQW051 2 mg (single and multiple doses)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01163227
Drug: AQW051 15mg (single and multiple doses)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01163227
Drug: AQW051 100mg (single dose), and 50mg (multiple doses)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02256709
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02256709
Drug: BIBP 5371 CL tablet high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02256709
Drug: Placebo drinking solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04105504
Drug: Glutathione
Normalized name: Glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glutathione capsule (500 mg), were taken once daily by the subjects.
Study: NCT04105504
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule were taken once daily by the subjects.
Study: NCT01857934
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00732537
Drug: inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNO started at 20 ppm for 1 hour, then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off). If \>5% drop in oxygen saturation was observed during weaning, study gas was increased to the previous concentration and weaning done 2 hourly. If \> 5% drop in oxygen saturation or \>5% Methemoglobin was observed during initial administration, the study gas would be weaned over 30 minutes and the infant would exit. The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. Monitoring of O2, NO2, NO was done by placing the end of the sample line inside the oxyhood. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment.
Study: NCT03643068
Drug: KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (0.6 mg dose).
Study: NCT02094365
Drug: vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03643068
Drug: KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (1.8 mg dose).
Study: NCT02280018
Drug: JNJ-49122944, 5 milligram (mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single dose of 5 mg JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
Study: NCT02280018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
Study: NCT00704236
Drug: Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica
Study: NCT00704236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03202615
Drug: F (ferrous sulphate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: FerroGrad by Abbott Dosage: one capsule three times /day containing150 mg of dried ferrous sulfate capsules (Ferrofol capsules, Eipico, Egypt), with placebo sachets.
Study: NCT01215968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT00865280
Drug: PTK 0796
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTK 0796 100 mg for injection; PTK 0796 tablet 150 mg
Study: NCT00050050
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00948441
Drug: 25% ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
Study: NCT00947882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 50 mg/mL solution
Study: NCT02644876
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation will be administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
Study: NCT01206218
Drug: FLOT Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
Study: NCT01206218
Drug: FLO Regimen or FLOT Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
Study: NCT01906762
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
Study: NCT04976543
Drug: nadroparin calcium-warfarin sequential anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The NWS therapy group were given a subcutaneous injection of nadroparin calcium every 12 hours for 1 month and switched to warfarin for 5 months. Warfarin was initiated at least 5 days before nadroparin calcium was stopped. International normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
Study: NCT03126318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water with a final buffer of 25 mM Histidine, 8.5% (w/v) trehalose and 0.05% PS80
Study: NCT00666016
Drug: TRO19622
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRO19622 500 mg once a day before noon meal during 6 weeks
Study: NCT02784067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucraid placebo
Study: NCT01420211
Drug: Primovist® 0,25 mmol/ml solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist® and blood sampling before (serum blank) and 6, 11, 21, 31, 45, 65, 95, 125 min and 3, 4, 6, 8, 12, 24 and 48 h after drug administration
Study: NCT02211170
Drug: BIBR 796 BS, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02211170
Drug: BIBR 796 BS, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02211170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00104520
Drug: AZLI 75 mg two times a day (BID)/three times a day (TID)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00104520
Drug: Placebo two times a day (BID)/three times a day (TID)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01080365
Drug: SKI-606 (Bosutinib)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg commercial formulation film coated tablet, administered once daily
Study: NCT01080365
Drug: SKI-606 (Bosutinib)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily
Study: NCT02379637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02339246
Drug: Prograf vs Astagraf XL vs Envarsus XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prograf vs Astagraf XL vs Envarsus XR
Study: NCT04635956
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
Study: NCT00823875
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine treatment
Study: NCT03795272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06143904
Drug: Genz-112638
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution-Route of administration:IV
Study: NCT06143904
Drug: Genz-112638
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Capsule-Route of administration:Oral
Study: NCT06143904
Drug: [14C]-Genz-112638
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution-Route of administration:Oral
Study: NCT02510560
Drug: NTRA-2112
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02510560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00152919
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04466670
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetylsalicylic acid (ASA) 100 mg daily PO up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
Study: NCT04466670
Drug: Unfractionated heparin nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: unfractionated heparin - 25,000 U/ 5 ml nebulized inhalation every 6 hours up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
Study: NCT04681105
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04681105
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03304938
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
Study: NCT01798849
Drug: MK-8892
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01798849
Drug: Placebo for MK-8892
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03535298
Drug: Early Highly Effective Therapies Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly Effective MS Therapy group of medications
Study: NCT03535298
Drug: Escalation Therapies Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalation MS Therapy group of medications
Study: NCT04279613
Drug: NNC0361-0041
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant supercoiled plasmid encoding four human proteins: (pre-proinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2) is administered s.c. via syringe and needle.
Study: NCT02929407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 2 of the trial, each subject will receive a 2 hour IV infusion of placebo.